碳离子放疗作为一种剂量递增治疗原发性高危前列腺癌的工具。

IF 2.2 3区医学 Q2 UROLOGY & NEPHROLOGY

Current Opinion in Urology Pub Date : 2025-09-01 Epub Date: 2025-07-17 DOI:10.1097/MOU.0000000000001327

Matthias Moll, Piero Fossati, Carola Lütgendorf-Caucig, Eugen Hug

{"title":"碳离子放疗作为一种剂量递增治疗原发性高危前列腺癌的工具。","authors":"Matthias Moll, Piero Fossati, Carola Lütgendorf-Caucig, Eugen Hug","doi":"10.1097/MOU.0000000000001327","DOIUrl":null,"url":null,"abstract":"Purpose of review: Prostate cancer is the most common cancer in men. In the high-risk group, carbon ion radiotherapy (CIRT) is being developed as a state-of-the-art alternative for treatment.Recent findings: Data conducted from studies in Japan, as published by the J-CROS group, suggest that CIRT provides a tool to deliver a treatment for high-risk prostate cancer that delivers tumour control similar to a brachytherapy boost, but without the associated increase in toxicity.Summary: While a considerable number of patients has been treated with CIRT, a randomized controlled trial showing the benefits of low toxicity while maintaining excellent tumour control has not yet been published and is highly warranted.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":"35 5","pages":"568-573"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Carbon ion radiotherapy as a dose escalation tool in the treatment of primary high-risk prostate cancer.\",\"authors\":\"Matthias Moll, Piero Fossati, Carola Lütgendorf-Caucig, Eugen Hug\",\"doi\":\"10.1097/MOU.0000000000001327\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose of review: Prostate cancer is the most common cancer in men. In the high-risk group, carbon ion radiotherapy (CIRT) is being developed as a state-of-the-art alternative for treatment.Recent findings: Data conducted from studies in Japan, as published by the J-CROS group, suggest that CIRT provides a tool to deliver a treatment for high-risk prostate cancer that delivers tumour control similar to a brachytherapy boost, but without the associated increase in toxicity.Summary: While a considerable number of patients has been treated with CIRT, a randomized controlled trial showing the benefits of low toxicity while maintaining excellent tumour control has not yet been published and is highly warranted.\",\"PeriodicalId\":11093,\"journal\":{\"name\":\"Current Opinion in Urology\",\"volume\":\"35 5\",\"pages\":\"568-573\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/MOU.0000000000001327\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOU.0000000000001327","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

综述目的：前列腺癌是男性最常见的癌症。在高危人群中，碳离子放射治疗（CIRT）正在发展成为一种最先进的治疗方法。最近的发现：J-CROS小组发表的日本研究数据表明，CIRT为高风险前列腺癌的治疗提供了一种工具，可以提供类似于近距离治疗的肿瘤控制，但没有相关的毒性增加。摘要：虽然相当多的患者已经接受了CIRT治疗，但一项随机对照试验显示，在保持良好的肿瘤控制的同时，低毒性的益处尚未发表，这是非常有根据的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Carbon ion radiotherapy as a dose escalation tool in the treatment of primary high-risk prostate cancer.

Purpose of review: Prostate cancer is the most common cancer in men. In the high-risk group, carbon ion radiotherapy (CIRT) is being developed as a state-of-the-art alternative for treatment.

Recent findings: Data conducted from studies in Japan, as published by the J-CROS group, suggest that CIRT provides a tool to deliver a treatment for high-risk prostate cancer that delivers tumour control similar to a brachytherapy boost, but without the associated increase in toxicity.

Summary: While a considerable number of patients has been treated with CIRT, a randomized controlled trial showing the benefits of low toxicity while maintaining excellent tumour control has not yet been published and is highly warranted.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Opinion in Urology 医学-泌尿学与肾脏学

CiteScore

5.00

自引率

4.00%

发文量

140

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Urology delivers a broad-based perspective on the most recent and most exciting developments in urology from across the world. Published bimonthly and featuring ten key topics – including focuses on prostate cancer, bladder cancer and minimally invasive urology – the journal’s renowned team of guest editors ensure a balanced, expert assessment of the recently published literature in each respective field with insightful editorials and on-the-mark invited reviews.